
    
      First, the investigators will document exposure to meropenem in plasma and epithelial lining
      fluid. Moreover excretion in urine will be documented.

      Second, the investigators will try to identify risk factors for not attaining PK/PD target.
      Based on significant predictors for target non attainment a predictive dosing algorithm will
      be constructed.

      Finally in a small subset of ECMO patients PK exposure will be explored.
    
  